Outcomes of Acute Kidney Injury After Pediatric Liver Transplantation: A 1‐Year Follow‐Up Authors: Jiemei Ji, Shengfeng Liang, Jian Lai, Zhongxuan Mao, Yunan Lin, Yuyan Lan, Jingchen Liu Published: 2024 ABSTRACT AbstractBackgroundPostoperative acute kidney injury (AKI) and chronic kidney disease (CKD) following pediatric liver transplantation (PLT) have not been comprehensively studied. This study aimed to evaluate the correlation between AKI and both 1‐year CKD and mortality.MethodsThis retrospective study included 132 children aged between 3 months and 12 years who underwent PLT between 2017 and 2021. Postoperative AKI and CKD after 1 year were assessed according to KDIGO criteria. AKI was classified as mild, moderate, or severe based on severity as well as transient (≤2 days) and persistent (>2 days) based on duration. CKD occurrence was the primary outcome, whereas all‐cause mortality was the secondary outcome.ResultsAKI developed in 45.4% of children, with 40.7% mild, 37.1% moderate, and 22.2% severe. Half of the children with AKI subsequently developed CKD within 1 year, compared to 23.1% without AKI. Multivariate analysis indicated that moderate AKI, severe AKI, and persistent AKI were risk factors for CKD development (moderate AKI, OR = 3.8, 95% CI = 1.2–12.3; severe AKI, OR = 7.4, 95% CI = 1.4–38.3; persistent AKI, OR = 9.7, 95% CI = 2.3–36.4). The overall mortality rate within 1 year after surgery was 9.8%. Children with severe AKI and AKI lasting longer than 2 days exhibited a higher mortality rate than those without AKI.ConclusionsThe development of postoperative AKI is relatively common after PLT, and the severity and duration of AKI are associated with CKD and mortality within 1 year. Introduction Pediatric liver transplantation (PLT) is considered an effective intervention to increase survival rates in children with congenital biliary atresia and inherited metabolic diseases that can cause end‐stage liver disease [1, 2]. Nevertheless, a subset of patients may develop renal insufficiency after PLT, potentially leading to the onset of post‐PLT complications. Recent studies in the adult population have revealed previously unknown complications of acute kidney injury (AKI) post‐liver transplantation. The incidence of AKI post‐liver transplantation in adults can vary between 36.1% and 71.4% [3, 4, 5], and is considered a prevalent adverse complication that is strongly associated with short‐term and long‐term morbidity and mortality [6, 7]. In adult liver transplantation, the development of chronic kidney disease (CKD) after a 6‐month follow‐up was 28.3% [8]. Notably, AKI is a significant contributor to CKD development in the long term [5]. Although the incidence of AKI and the relationship between AKI and CKD in adult liver transplantation have been previously reported, they have rarely been described following PLT. Two retrospective studies demonstrated that the occurrence of AKI in pediatric patients undergoing liver transplantation was 46.2% and 57%, respectively, with variations in the incidence of the three stages of AKI [9, 10]. Moreover, the prevalence of CKD has been reported to range from 3% to 33% after a decade of monitoring following PLT [11, 12, 13]. A retrospective cohort study reported that children with diminished renal function exhibited a cumulative incidence rate of 7.2% for CKD stage ≥3 during 14 years of monitoring in pediatric patients following liver transplantation [14]. Nevertheless, the relationship between AKI and CKD has not been investigated in the context of PLT, and findings from non‐PLTs (including cardiac and non‐cardiac surgeries) have been inconsistent. A comprehensive analysis of 10 cohort studies reported that AKI is associated with an increased likelihood of the development of renal consequences in children [15]. However, prospective and retrospective cohort studies on pediatric patients who underwent cardiac or major noncardiac surgeries reported no such correlation [16, 17]. Currently, there are discrepancies in the reported prevalence of AKI in children after liver transplantation, and there is a lack of research on the correlation between post‐liver transplant AKI and CKD. We conducted a retrospective cohort study on PLT recipients. We investigated the association between post‐liver transplant AKI development, an exposure variable, and CKD occurrence within 1 year of follow‐up. We also investigated the 1‐year mortality rate associated with post‐liver transplant AKI. We hypothesized that children who develop postoperative AKI may have an increased likelihood of developing CKD and mortality within 1 year compared with those without AKI. Materials and Methods Study Design and Patient Selection This retrospective cohort study was approved by the Ethics Committee of First Affiliated of Guangxi Medical University (Approval No.: 2022‐K080‐01) and conformed to the ethical guidelines of the Declaration of Helsinki. Verbal informed consent was obtained from all the patients’ parents. In total, 137 children under the age of 12 years underwent liver transplantation between January 1, 2017 and December 31, 2021. None of these 137 children used the livers of executed prisoners. The exclusion criteria were as follows: children diagnosed with preoperative renal failure requiring kidney replacement therapy, those with CKD, and those who underwent secondary liver transplantation or combined organ transplantation. The flow chart of the study is shown in Figure 1. Flow diagram of the children included in this study. Children who underwent PLT experienced liver failure before surgery and were classified as Grades IV–V by the American Society of Anesthesiologists (ASA) classification system. General anesthesia was used for all surgical procedures. After surgery, all children were moved to the pediatric intensive care unit for regular monitoring. We obtained the urine output within 24 h post‐operation (recorded every 4 h) and serum creatinine values on postoperative Days 1, 2, 3, 4, 5, and 7 for pediatric patients from the hospital information system. Further, all children were monitored for 1 year following enrollment in the study, during which their estimated Glomerular Filtration Rate (eGFR) and survival status were recorded monthly. AKI occurring within 7 days following the surgical procedure was considered the exposure variable. This was determined based on the criteria of the Kidney Disease: Improving Global Outcomes (KDIGO) [18], which considers an increase in serum creatinine levels or urine volume (Table 1). We documented the stages of AKI as well as the onset of AKI and its duration in days, categorizing the duration of AKI into two groups: “transient” for AKI lasting 2 days or less and “persistent” for AKI lasting more than 2 days. TABLE 1Proposed KDIGO staging of AKI.StageSerum creatinineUrine outputMild 1.5–1.9 times baseline Or ≥0.3 mg/dL (≥26.5 mol/L) increase <0.5 mL/kg/h for 6–12 hModerate2.0–2.9 times baseline<0.5 mL/kg/h for ≥12 hSevere 3 times baseline Or ≥4.0 mg/dL (≥353.6 mol/L) increase Or initiation of RRT <0.3 mL/kg/h for ≥24 h Or anuria ≥12 h John Wiley & Sons, Ltd. Proposed KDIGO staging of AKI. 1.5–1.9 times baseline Or ≥0.3 mg/dL (≥26.5 mol/L) increase 3 times baseline Or ≥4.0 mg/dL (≥353.6 mol/L) increase Or initiation of RRT <0.3 mL/kg/h for ≥24 h Or anuria ≥12 h Outcome Assessment We focused on the development of CKD within 1 year of follow‐up, with a secondary focus on all‐cause mortality at 1 year. CKD was defined using the KDIGO criteria based on abnormal eGFR persisting for 3 months or more [19]. eGFR was estimated using the bedside creatinine‐based CKD in the children study equation [20]. Because eGFR increases physiologically until the age of 2 years, so we defined low eGFR using published normative data adjusted for age as follows [21]: <8 months old, <58 mL/min per 1.73 m2; ≥8–12 months old, <65 mL/min per 1.73 m2; ≥12–18 months old, <74 mL/min per 1.73 m2; ≥18–24 months old, <76 mL/min per 1.73 m2; ≥2 years old, <90 mL/min per 1.73 m2. Statistical Analysis Data are presented as mean ± standard deviation (SD) or median (interquartile range) for continuous variables and as frequency or percentage for categorical variables. The four groups (no, mild, moderate, and severe AKI) were compared for each covariate (Table 2). Continuous variables were assessed using the t‐test for normally distributed data or the Kruskal–Wallis rank sum test for non‐normally distributed data. Categorical variables were analyzed using the chi‐squared test (Table 2). TABLE 2Demographic and clinical characteristics of the study population (N = 119).FactorNo postoperative AKI (N = 65)Mild AKI (N = 22)Moderate AKI (N = 20)Severe AKI (N = 12) p valueAge, months10.0 [7.0–44.0]7.5 [6.0–14.0]7.0 [5.8–12.0]13.5 [8.8–35.5]0.087BMI, kg/m2 17.0 ± 3.316.4 ± 2.216.2 ± 2.016.1 ± 2.40.419Sex0.916Female27 (41.5)11 (50.0)9 (45.0)5 (41.7)Male38 (58.5)11 (50.0)11 (55.0)7 (58.3)Growth disorder0.659No34 (52.3)13 (59.1)13 (65.0)8 (66.7)Yes31 (47.7)9 (40.9)7 (35.0)4 (33.3)Etiology0.653Congenital biliary atresia51 (78.5)14 (63.6)17 (85.0)9 (75.0)Inherited metabolic diseases a 5 (7.7)2 (9.1)0 (0.0)1 (8.3)Others b 9 (13.8)6 (27.3)3 (15.0)2 (16.7)ABO blood group0.416Compatibility44 (67.7)18 (81.8)13 (65.0)10 (83.3)Incompatibility21 (32.3)4 (18.2)7 (35.0)2 (16.7)Child‐Pugh grade0.846Grade A10 (15.4)4 (18.2)1 (5.0)3 (25.0)Grade B24 (36.9)8 (36.4)8 (40.0)4 (33.3)Grade C31 (47.7)10 (45.5)11 (55.0)5 (41.7)PELD, score12.0 (6.0–18.0)15.5 (4.8–19.0)14.0 (4.5–22.0)14.0 (3.8–15.8)0.790Preoperative status0.940ICU6 (9.2)2 (9.1)1 (5.0)0 (0.0)Hospitalized22 (33.8)8 (36.4)8 (40.0)5 (45.5)Home37 (56.9)12 (54.5)11 (55.0)6 (54.5)Liver donor0.200Living‐related liver50 (76.9)18 (81.8)15 (75.0)6 (50.0)Deceased liver15 (23.1)4 (18.2)5 (25.0)6 (50.0)Donor age (parents), years32.1 ± 6.434.6 ± 4.834.1 ± 6.234.3 ± 6.10.400Donor age (deceased), years3.0 (1.8–5.6)3.2 (1.9–7.2)7.8 (3.4–12.5)1.0 (0.9–6.0)0.428Preoperative albumin, g/L36.3 ± 7.834.8 ± 4.735.7 ± 6.337.6 ± 6.40.712Ascites0.583No17 (26.2)4 (18.2)2 (10.0)3 (25.0)Mild37 (56.9)16 (72.7)16 (80.0)7 (58.3)Severe11 (16.9)2 (9.1)2 (10.0)2 (16.7)Noradrenaline, µg/kg8.1 [0.0–28.3]10.4 [3.0–26.6]10.9 [0.6–24.9]15.5 [2.3–36.4]0.895Ulinastatin0.410No39 (60.0)13 (59.1)11 (55.0)10 (83.3)Yes26 (40.0)9 (40.9)9 (45.0)2 (16.7)Cold ischemia time, min123.0 [93.0–185.0]125.0 [91.2–181.8]123.5 [108.8–175.2]177.5 [124.8–307.5]0.278Warm ischemia time, min49.4 ± 15.947.5 ± 15.251.7 ± 17.463.4 ± 19.10.122Anhepatic phase, min54.8 ± 18.853.6 ± 17.151.0 ± 17.663.6 ± 19.50.305Anhepatic urine, mL/kg1.4 [0.7–3.3]2.2 [1.0–4.6]3.2 [1.9–8.8]1.9 [1.2–4.2]0.051Blood loss, mL/kg46.7 [24.1–77.3]65.9 [40.7–96.9]65.7 [42.7–80.4]56.3 [39.6–78.5]0.279Transfusion of blood productsRed blood cells, U/kg0.2 [0.1–0.5]0.4 [0.3–0.6]0.4 [0.3–0.5]0.4 [0.3–0.7]0.044Plasma, U/kg33.3 [19.3–55.4]51.3 [36.8–67.3]42.9 [28.4–59.1]35.0 [24.1–68.7]0.085Platelet0.607No60 (92.3)21 (95.5)20 (100)11 (91.7)Yes5 (7.7)1 (4.5)0 (0.0)1 (8.3)Cryoprecipitate0.671No63 (96.9)20 (90.9)19 (95.0)11 (91.7)Yes2 (3.1)2 (9.1)1 (5.0)1 (8.3)Crystalloid infusion, mL/kg73.0 [48.0–128.9]101.4 [64.8–182.9]123.6 [65.8–187.4]114.1 [64.7–246.7]0.126Human albumin, g/kg2.5 [1.6–3.6]2.6 [1.7–4.3]3.8 [2.7–4.9]2.9 [2.2–5.4]0.190Operative duration (min)591.9 ± 121.5672.2 ± 254.4625.4 ± 220.9683.2 ± 184.70.370Anesthesiology duration (min)736.1 ± 137.2837.9 ± 327.2765.6 ± 225.6813.2 ± 170.50.484Postop ICU stay duration (h)91.0 [72.0–134.0]89.5 [79.2–118.8]112.5 [90.7–210.0]129.5 [90.8–210.8]0.195Postop mechanical ventilation duration (h)39.0 [15.8–62.3]38.8 [18.2–82.0]44.0 [18.8–83.7]39.0 [30.4–75.2]0.517Postop‐discharge Duration (day)32.0 [27.0–40.0]34.5 [26.2–39.0]34.5 [29.8–41.2]35.5 [20.0–56.5]0.767Hospitalization cost (thousand Yuan)178.1 ± 66.4166.7 ± 60.0206.5 ± 64.6219.2 ± 65.40.051Immunosuppressive protocolIncluding tacrolimus62 (95.4)19 (86.4)16 (80.8)11 (91.7)0.558Including medrol46 (70.8)16 (72.7)12 (60.0)10 (83.3)Complications c 0.422No45 (69.2)15 (68.2)15 (75.0)11 (91.7)Yes20 (30.8)7 (31.8)5 (25.0)1 (8.3) Note: Summary statistics are presented as mean ± SD (standard deviation); data are mean ± SD, Median [Q1–Q3], or N (%).Abbreviation: AKI, acute kidney injury. a Inherited metabolic diseases included one case of bile acid synthesis defect, one case of tyrosinemia type I, one case of hepatolenticular degeneration, one case of glycogen‐storage disease, one case of acquired vitamin K‐dependent coagulation factors abnormalities, two cases of familial intrahepatic cholestasis, and one case of disease associated with abnormal ketone metabolism. b Others included: five cases of hepatic neuroblastoma, three cases of portal cavernous transformation, three cases of Budd–Chiari syndrome, one case of Abernethy malformation (absence of portal vein), two cases of congenital liver fibrosis leading to cirrhosis, one case of Langerhans cell hyperplasia, two cases of fulminant hepatic failure, one case of essential thrombocytopenia, and two cases of intrahepatic bile duct dysplasia. c Complications: intra‐abdominal hemorrhage/effusion/abscess, bile leaks, wound infections, pulmonary infections, pulmonary edema, hepatic artery embolism or necrosis of Roux‐en‐Y biliary loop requiring reoperation, acute rejection, graft‐versus‐host disease, chylothorax, intestinal obstruction, and bile duct dilation.John Wiley & Sons, Ltd. Demographic and clinical characteristics of the study population (N = 119). Note: Summary statistics are presented as mean ± SD (standard deviation); data are mean ± SD, Median [Q1–Q3], or N (%). Abbreviation: AKI, acute kidney injury. Inherited metabolic diseases included one case of bile acid synthesis defect, one case of tyrosinemia type I, one case of hepatolenticular degeneration, one case of glycogen‐storage disease, one case of acquired vitamin K‐dependent coagulation factors abnormalities, two cases of familial intrahepatic cholestasis, and one case of disease associated with abnormal ketone metabolism. Others included: five cases of hepatic neuroblastoma, three cases of portal cavernous transformation, three cases of Budd–Chiari syndrome, one case of Abernethy malformation (absence of portal vein), two cases of congenital liver fibrosis leading to cirrhosis, one case of Langerhans cell hyperplasia, two cases of fulminant hepatic failure, one case of essential thrombocytopenia, and two cases of intrahepatic bile duct dysplasia. Complications: intra‐abdominal hemorrhage/effusion/abscess, bile leaks, wound infections, pulmonary infections, pulmonary edema, hepatic artery embolism or necrosis of Roux‐en‐Y biliary loop requiring reoperation, acute rejection, graft‐versus‐host disease, chylothorax, intestinal obstruction, and bile duct dilation. We considered 1‐year CKD as the outcome variable, whereas postoperative AKI (categorized as none, mild, moderate, or severe) and all other covariates were considered as independent variables. Univariate regression analysis was performed to identify potential risk factors and confounding variables (Table 3). AKI (categorized as present or absent) was considered as a dichotomous variable to perform covariate checks and screening. After covariates were introduced into the basic model or eliminated from the complete model, adjusting factors were selected based on their influence on the regression coefficient of AKI (>10%) or CKD (p < 0.1). Multivariate regression models were constructed to analyze the independent effects of postoperative AKI on CKD (Table 3). The effects of postoperative AKI on 1‐year all‐cause mortality were evaluated using Kaplan–Meier curves (long‐rank test) and Cox univariate logistic regression (Table 4). TABLE 3Uni‐ and multi‐variate regression model for risk factors associated with 1‐year CKD following PLT surgery.VariablesUnivariate p valueMultivariate p valueAge, months0.994 (0.983, 1.006)0.335Child‐Pugh gradeGrade AReferenceReferenceGrade B2.333 (0.580, 9.392)0.2332.004 (0.395, 10.171)0.401Grade C3.906 (1.017, 15.000)0.0474.408 (0.672, 28.917)0.1222Postop ICU stay duration (hours)1.007 (1.002, 1.011)0.0091.006 (1.000, 1.012)0.045Postop mechanical ventilation duration (h)1.008 (1.001, 1.015)0.0331.007 (0.999, 1.016)0.092Postoperative AKINoReferenceReferenceMild2.727 (0.951, 7.818)0.0622.767 (0.817, 9.365)0.102Moderate2.778 (1.003, 7.691)0.0493.818 (1.184, 12.311)0.025Severe6.667 (1.760, 25.251)0.0057.408 (1.432, 38.316)0.017Postoperative AKINoReferenceReferenceTransient (≤2 days)2.333 (0.954, 5.705)0.0632.548 (0.917, 7.075)0.073Persistent (>2 days)6.190 (2.092, 18.321)0.0019.710 (2.310, 36.400)0.002 Note: Data are odds ratio with 95% CI.Abbreviations: AKI, acute kidney injury; CI, confidence interval; CKD, chronic kidney dysfunction. OR, odds ratio; PLT, pediatric liver transplantation.John Wiley & Sons, Ltd. Uni‐ and multi‐variate regression model for risk factors associated with 1‐year CKD following PLT surgery. Note: Data are odds ratio with 95% CI. Abbreviations: AKI, acute kidney injury; CI, confidence interval; CKD, chronic kidney dysfunction. OR, odds ratio; PLT, pediatric liver transplantation. TABLE 4Comparison of 1‐year mortality after PLT surgery for postoperative AKI.Postoperative AKI No death n (%) One‐year mortality n (%) HR (95% CI) p valueStagesNo67 (93.1)5 (6.9)Reference—Mild21 (95.5)1 (4.5)0.661 (0.077, 5.673)0.706Moderate19 (90.5)2 (9.5)1.408 (0.273, 7.260)0.683Severe12 (70.6)5 (29.4)5.297 (1.529, 18.354)0.009DurationNo67 (93.1)5 (6.9)Reference—Transient33 (97.1)1 (2.9)0.423 (0.049, 3.622)0.432Persistent19 (73.1)7 (26.9)4.340 (1.375, 13.698)0.012Abbreviations: AKI, acute kidney injury; CI, confidence interval; HR, hazard ratio.John Wiley & Sons, Ltd. Comparison of 1‐year mortality after PLT surgery for postoperative AKI. No death n (%) One‐year mortality n (%) Abbreviations: AKI, acute kidney injury; CI, confidence interval; HR, hazard ratio. The data were entered twice and exported to tab‐delimited text files. A p value of <0.05(two‐tailed) was considered statistically significant. The statistical software packages R (http://www.R‐project.org, The R Foundation) and EmpowerStats (www.empowerstats.com, X&Y Solutions, Inc., Boston, MA) were used for performing all analyses. Results AKI at 7 Days and CKD at 1 Year After PLT Surgery Among the 119 patients included in the study, the incidence of AKI following PLT surgery was 24.4%, 16.8%, 22.7%, 19.3%, 10.1%, and 16.8% on Days 1, 2, 3, 4, 5, and 7, respectively. A total of 54 AKI cases occurred within 7 days, accounting for 45.4% of the total cases, with 40.7% classified as mild, 37.1% as moderate, and 22.2% as severe. Furthermore, 44.4% of the children experienced AKI lasting only 1 day, while the incidence of AKI lasting 2, 3, 4, 5, and 6 days was 18.5%, 9.3%, 11.1%, 11.1%, and 5.6%, respectively. Therefore, there were 34 cases (28.6%) of transient AKI and 20 cases (16.8%) of persistent AKI. The demographic and clinical characteristics of these patients, including the underlying causes of intraoperative and postoperative factors, are summarized in Table 2. No statistically significant difference was found in the baseline characteristics among the four AKI groups, except for the amount of intraoperative red blood cell transfusions (p = 0.04). Twenty‐seven of 54 children (50%) who experienced AKI following PLT surgery progressed to CKD within 1 year. In contrast, 15 of the 65 children without AKI developed CKD. The eGFR decreased in 60.5% of the children with CKD within the first month post‐surgery. The incidence of decline in initial eGFR in children with CKD were 15.8%, 5.3%, 13.2%, 2.6%, and 2.6% at 2, 3, 4, 5, and 6 months, respectively. Relationship Between Postoperative AKI and 1‐Year CKD The results of univariate regression analysis suggested that preoperative Child‐Pugh grade C liver function, the duration of postoperative ICU stay and mechanical ventilation, moderate and severe AKI, and persistent AKI may be significant factors affecting the development of 1‐year CKD in pediatric patients following liver transplantation (Table 3). Furthermore, potential confounding covariates were evaluated and screened, including preoperative status, Child‐Pugh grade, degree of ascites, intraoperative warm and cold ischemia time, duration of postoperative ICU stay and mechanical ventilation, use of human albumin, and immunosuppressive regimens involving tacrolimus. After controlling for potential confounding variables using multivariate analysis, our study revealed that moderate AKI, severe AKI, persistent AKI, and the duration of postoperative ICU stay were all significantly correlated with the occurrence of CKD within 1‐year post‐PLT (Table 3). Relationship Between Postoperative AKI and 1‐Year Mortality Of the 132 children included in the study, 13 died within 1 year after surgery, resulting in an overall mortality rate of 9.8%. Specifically, children with severe AKI exhibited a mortality rate of 29.4%, whereas those without AKI still faced a mortality rate of 6.9%. The risk of mortality was notably elevated in children with severe AKI, showing a 4.3‐fold increase compared with those without postoperative AKI (Figure 2A and Table 4). Moreover, the study revealed that children with persistent AKI had a 3.3‐fold higher risk of death than those without AKI, whereas there was no statistically significant difference in mortality rates between children with transient AKI and those without AKI (Figure 2B and Table 4). Relationship between postoperative acute kidney injury (AKI) and 1‐year mortality in pediatric liver transplantation (PLT). Stage (A) and duration (B) of AKI have an impact on the 1‐year mortality of children. The 1‐year mortality rate in children with severe and persistent AKI was significantly higher than that in children without AKI. The causes of death were liver‐associated complications in four cases (occurring on postoperative Days 9, 13, 16, and 67), acute renal failure in one case (occurring on the 8th postoperative day), multiple organ dysfunction syndrome in five cases (occurring on postoperative Days 18, 88, 194, 329, and 355), hypovolemic shock in one case (occurring on postoperative Day 133), acute respiratory distress syndrome in one case (occurring on postoperative Day 83), and sepsis in one case (occurring on postoperative Day 161). Discussion We found that the incidence of postoperative AKI following liver transplantation in children was 45.4% (54 out of 119), which is consistent with the results reported by Hamada et al. [9]. However, the occurrence of AKI in children has not been reported consistently. A prospective cohort study involving children aged 1 month–18 years reported an AKI incidence rate of 25%–60% post‐cardiac [22]. A retrospective cohort analysis including pediatric patients aged 18 years and younger reported an AKI incidence of 11% after non‐cardiac surgery [23]. Among individuals aged 3 months–25 years, the incidence of AKI in the ICU was 26.9% [24]. Additionally, a multicenter study focusing on hospitalized children aged 1 month–18 years reported a 13% prevalence of AKI during hospitalization [25]. Studies of the severity and duration of AKI and its long‐term association with CKD in children are limited. Our study reported that a significant proportion of children with mild, moderate, and severe AKI developed CKD, with incidence rates of 45.5%, 45.0%, and 66.7%, respectively, within 1‐year post‐PLT. Furthermore, we identified that moderate and severe, were independent risk factor for 1‐year CKD, and the duration of AKI greater than 2 days was an independent risk factor for 1‐year CKD. These findings are inconsistent with those of a previous study performed on adults, which reported that even mild cases of AKI following intermediate‐ to high‐risk surgeries are associated with long‐term renal damage [26]. However, a prospective cohort study including children aged 1 month–18 years reported a high prevalence of CKD 4 year's post‐cardiac surgery. AKI was not associated with the development of CKD but rather with young age [16]. Conversely, a different study did not find any association between postoperative AKI and CKD following major surgery lasting over 2 h, both in cardiac and non‐cardiac patients aged 2–18 years [17]. Due to variations in the prevalence of pediatric AKI and the ambiguous association between postoperative AKI and CKD, the following five factors should be considered with caution while drawing conclusions from our study. Inconsistencies in the demographics of the study cohorts, including age, surgical status, and surgical procedure, were observed. Notably, the ages of the children involved in these studies varied, and a distinction exists between nonsurgical patients, including hospitalized patients, and surgical patients, including those undergoing cardiac, non‐cardiac, or other surgical interventions. This study focused on pediatric patients undergoing major liver transplant surgery, because occlusion of the inferior vena cava and portal vein during the procedure leads to hemodynamic instability and renal insufficiency. The second aspect that should be considered is the study design, whether it is a prospective or retrospective analysis performed at a single‐center or multi‐centers. Third, the duration of surgery was identified as a significant factor. Our study showed that surgeries lasting for over 10 h exhibit a potentially increased risk of AKI. The fourth reason pertains to the variability in the follow‐up period, ranging from 1 to 4 years in the studies analyzed. We found that an increased length of follow‐up was associated with a decreasing trend in CKD among individuals with AKI. Our study only included a 1‐year retrospective follow‐up. Finally, the results cannot be directly compared owning to the different definitions of AKI and CKD. The inclusion of urine output in the AKI criteria was not common in several studies. However, our study could obtain these data because pediatric patients were admitted to a pediatric ICU for post‐surgical observation and treatment. Consequently, a detailed recording of urine output was obtained and incorporated into the criteria, potentially affecting the risk assessment of AKI. This study revealed that 23.1% (15 out of 65) of children who did not have AKI still experienced CKD development within 1‐year post‐surgery. This phenomenon may have occurred because the children who underwent PLT were classified as ASA IV–V, along with liver failure or more severe complications, which may have contributed to the onset of 1‐year CKD. Information on pediatric patients who underwent liver transplantation was recorded in the National Liver Transplantation Registration Management System. Dedicated personnel were responsible for data entry and long‐term follow‐ups. This ensures the availability of data on the creatinine concentration of each patient for 1‐year post‐operation, eliminating any potential loss due to follow‐up bias. Furthermore, postoperative AKI was categorized as mild, moderate, severe, and transient or persistent for analysis. This approach provides an in‐depth understanding of the correlation between postoperative AKI and CKD within a 1‐year period. A study in adults reported that postoperative AKI was associated with the progression of CKD, but not its severity [27]. In contrast, our research demonstrated a correlation between postoperative AKI and CKD, with a higher likelihood of CKD development after post‐PLT surgery in cases of moderate to severe AKI. Moreover, our findings showed that AKI lasting longer than 2 days may further elevate the risk of 1‐year CKD, aligning with a previous study conducted by Mehta et al. [28]. Nevertheless, our results may have been affected by potential confounding factors, such as intraoperative hypotension, administration of vasoactive agents, and use of postoperative intravenous fluids. While the use of intraoperative epinephrine was considered in our study, it is worth noting that only the total doses were recorded without specific consideration of the duration and concentration. Our study showed that AKI is associated with all‐cause mortality within 1 year of liver transplantation, and severe AKI and a duration longer than 2 days are associated with an increased rate of 1‐year mortality. Notably, graft nonfunction is the primary cause of short‐term mortality rather than renal failure. Therefore, clinicians should prioritize the maintenance of overall organ functions in patients with PLT. It is also worth noting that surgeons, anesthesiologists, and intensive care physicians should enhance their awareness of the prevention and treatment of postoperative AKI, as pediatric patients may enjoy a longer post‐transplant life than adults. This study had some limitations that should be addressed. This study had a retrospective observational design; therefore, we could not control all confounding factors and biases. Despite our efforts to include all established risk factors and variables associated with postoperative AKI and 1‐year CKD, some potential factors may still be present, such as intravenous fluid therapy and fasting hours. These factors may vary based on the clinicians, patients, and clinically relevant practices; therefore, they can potentially introduce confounding effects into our results. Another limitation of this study is that we focused on a single institution and the number of participants was relatively limited. To gain a more definitive understanding of the correlation between AKI in PLT and adverse long‐term renal function, extensive studies involving adequately matched cohorts are warranted. In conclusion, postoperative acute kidney injury is common among PLT recipients. Furthermore, moderate to severe AKI and an AKI duration longer than 2 days are associated with the progression of CKD within the first year following surgery. Moreover, the presence of severe AKI and an AKI duration exceeding 2 days correlated with higher 1‐year mortality rates. Author Contributions Jiemei Ji: methodology, data curation, formal analysis, writing‐original draft, visualization. Shengfeng Liang: data curation, investigation, visualization. Jian Lai: methodology, conceptualization, investigation, writing‐review & editing. Zhongxuan Mao: investigation, data curation, visualization. Yunan Lin: resources, software, writing‐review & editing. Jingchen Liu: supervision, writing‐review & editing, project administration. Yuyan Lan: conceptualization, methodology, writing‐review & editing, supervision, project administration. Conflicts of Interest The authors report no conflicts of interest.